Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The current approach of morbidity control of schistosomiasis, a helminth disease of poverty with considerable public health and socioeconomic impact, is based on preventive chemotherapy with praziquantel. There is a pressing need for new drugs against this disease whose control entirely depends on this single drug that has been widely used over the past 40 years. We argue that a broader anthelminthic approach supplementing praziquantel with new antischistosomals targeting different parasite development stages would not only increase efficacy but also reduce the risk for drug resistance. Repositioning drugs already approved for other diseases provides a shortcut to clinical trials, as it is expected that such drugs rapidly pass the regulatory authorities. The antischistosomal properties of antimalarial drugs (e.g., semisynthetic artemisinins, synthetic trioxolanes, trioxaquines and mefloquine) and of drugs being developed or registered for other purposes (e.g., moxidectin and miltefosin), administered alone or in combination with praziquantel, have been tested in the laboratory and clinical trials. Another avenue to follow is the continued search for new antischistosomal properties in plants. Here, we summarise recent progress made in schistosomiasis chemotherapy, placing particular emphasis on repositioning of existing drugs against schistosomiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kassebaum, N. J., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, J., Carter, A., Casey, D. C., Charlson, F. J., Coates, M. M., Coggeshall, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31460-x · Cited by 2,163
Qinghaosu (Artemisinin): The Price of Success
White, N. J. (2008) · Science · doi:10.1126/science.1155165 · Cited by 954 · cited 1×
“Briefly, leaf extracts from the plant Artemisia annua recommended in Chinese traditional medicine against malaria (and other ailments), constituted the starting point for the development of the artemisinin-based combination therapy (ACT) currently in use against this infection [92, 93].”
BackgroundMolyneux, D. H., Hotez, P. J., & Fenwick, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020336 · Cited by 557 · cited 1×
“The disease is one of today’s foremost neglected tropical diseases (NTDs) and a disease of poverty [3, 4].”
BackgroundGrimes, J. E. T., Croll, D., Harrison, W. E., Utzinger, J., Freeman, M. C., & Templeton, M. R. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003296 · Cited by 296
The Drugs We Have and the Drugs We Need Against Major Helminth Infections
Keiser, J., & Utzinger, J. (2010) · Advances in Parasitology · doi:10.1016/s0065-308x(10)73008-6 · Cited by 288
Self-citationChemistry and Pharmacology of Neglected Helminthic Diseases
Mullner, A., Helfer, A., Kotlyar, D., Oswald, J., & Efferth, T. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794480096 · Cited by 23
Cited by
The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand
Chan, J. D., Cupit, P. M., Gunaratne, G. S., McCorvy, J. D., Yang, Y., Stoltz, K., Webb, T. R., Dosa, P. I., Roth, B. L., Abagyan, R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02084-0 · Cited by 69
Beutler, M., Harnischfeger, J., Weber, M. H. W., Hahnel, S. R., Quack, T., Blohm, A., Ueberall, M. E., Timm, T., Lochnit, G., Rennar, G. A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115179 · Cited by 10
Metadata
- Authors
- Bergquist, R., Utzinger, J., & Keiser, J.
- Venue
- Infectious Diseases of Poverty
- Published
- 2017-03-28
- Volume
- 6
- Issue
- 1
- Pages
- 74-74
- ISSN
- 2049-9957 (ISSN-L)
- OpenAlex
- W2599189039
- Cited by
- 195
- References
- 6
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? https://app.cochat.ai/papers/10.1186/s40249-017-0286-2
- The paper
- Bergquist, R., Utzinger, J., & Keiser, J. (2017). Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? Infectious Diseases of Poverty. https://doi.org/10.1186/s40249-017-0286-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.